SCHEMBL14645295

SCHEMBL14645295

O=C(O)CCc1cc(-c2ccccc2C(=O)O)sc1-c1ccc(-c2sc(-c3ccccc3C(=O)O)cc2CCC(=O)O)s1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 7/20 0.44
PTGER4 P35408 7/20 0.44
PTGER3 P43115 7/20 0.44
PTGER2 P43116 7/20 0.44
FOLH1 Q04609 3/20 0.38
NPSR1 Q6W5P4 1/20 0.37
RPS6KB2 Q9UBS0 1/20 0.37
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
KEAP1 Q14145 1/20 0.36
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.35
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
LTB4R Q15722 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14646163 0.95 PTGER1 (0.48) PTGER1PTGER4PTGER3PTGER2FOLH1
SCHEMBL17803968 0.89 HPGD (0.45) PTGER1PTGER4PTGER3PTGER2NPSR1
SCHEMBL14645294 0.86 FOLH1 (0.41) FOLH1ALDH1A1KDM4EUSP2TSHR
SCHEMBL14646259 0.84 PTGER4 (0.50) PTGER1PTGER4PTGER3PTGER2NPSR1
SCHEMBL14646253 0.83 PTGER4 (0.49) PTGER1PTGER4PTGER3PTGER2NPSR1
SCHEMBL14646239 0.82 FOLH1 (0.40) PTGER1PTGER4PTGER3PTGER2FOLH1
SCHEMBL14646196 0.82 FOLH1 (0.40) PTGER1PTGER4PTGER3PTGER2FOLH1
SCHEMBL14646236 0.81 PTGER4 (0.52) PTGER1PTGER4PTGER3PTGER2RPS6KB2
SCHEMBL14646254 0.81 PTGER4 (0.52) PTGER1PTGER4PTGER3PTGER2RPS6KB2
SCHEMBL15695253 0.80 MYC (0.40) FOLH1ALDH1A1HPGDKDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 US disclosed
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 US disclosed
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 US disclosed
EP-2817304-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BioChromix NewCo AB (SE) 2014-12-31 EP disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 US disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY PRNP, TBCA, HSPA5 PTGER1 3768/4885PTGER4 4654/4885PTGER3 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.